Sun Pharma and Daiichi Sankyo, the previous owner of Ranbaxy, together hold 66.85 per cent shares in the near-defunct subsidiary, while the previous promoter Jayaram Chigurupati and his family own 23.91 per cent shares.
“As on March 2015, the total net worth of the company has been completely eroded. The board of directors has formed an opinion that the company has become a sick industrial company under the provisions of the Sick Industrial Companies (Special Provisions) Act 1985 and necessary reference shall be made to the BIFR in due course of time,” Zenotech chairman Vijay Agarwal said in a filing to the stock exchanges.
In 2007, Ranbaxy took control of the company by enhancing its equity holding to 45 per cent for a consideration of over Rs 200 crore as it wanted to expand its product portfolio by acquiring this biopharmaceutical company. However, in the subsequent years, there was an ugly spat erupted between the previous promoter and the new owner of the company with Jayaram Chigurupati filing a case against Ranbaxy accusing it of criminal breach of trust soon after Daiichi acquired Ranbaxy.
Further in June last year, some petitioners, claiming to be the minority shareholders of Zenotech, approached the AP high court and got interim orders, though lasted only for a brief period, against the Sun-Ranbaxy merger.
During the fourth quarter ended March 2015, Zenotech has reported a net loss of Rs 10.70 crore, as compared with a net loss of Rs 2.6 crore in the corresponding quarter. Revenues for the quarter under review stood at just Rs 89.12 lakh.
The books of records, supplementary documents and statutory registers up till November 12, 2014, are still not in the possession of the company though the Company Law Board in October 2012 had directed Jayaram Chigurupati to return all the documents and provide written details of all missing documents assets etc of the company, according to the filing. The total equity and liabilities of the company were shown as Rs 63.71 crore as at March 2015.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)